{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:24:52Z","timestamp":1787898292745,"version":"build-2784847793"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.mce.2025.112598","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:31:04Z","timestamp":1749090664000},"page":"112598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology"],"prefix":"10.1016","volume":"607","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7404-6464","authenticated-orcid":false,"given":"LS","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HW","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SJ","family":"Ramus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AI","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib1","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","article-title":"DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities","volume":"54","author":"Abuetabh","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/en.2010-0886","article-title":"Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis","volume":"152","author":"Al-Azzawi","year":"2011","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr. Pathol."},{"issue":"6","key":"10.1016\/j.mce.2025.112598_bib95","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2018.2.FOCUS17660","article-title":"Regression of a nonfunctioning pituitary macroadenoma on the CDK4\/6 inhibitor palbociclib: case report","volume":"44","author":"Anderson","year":"2018","journal-title":"Neurosurg Focus"},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4161\/cc.8.5.8065","article-title":"Pituitary adenoma growth: a model for cellular senescence and cytokine action","volume":"8","author":"Arzt","year":"2009","journal-title":"Cell Cycle Georget. Tex."},{"issue":"7403","key":"10.1016\/j.mce.2025.112598_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib7","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/jc.2014-4350","article-title":"Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide","volume":"100","author":"Bengtsson","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.mce.2025.112598_bib8","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1210\/jc.2017-01401","article-title":"Corticotroph pituitary carcinoma in a patient with lynch syndrome (LS) and pituitary tumors in a nationwide LS cohort","volume":"102","author":"Bengtsson","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/sj.cdd.4402254","article-title":"Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin","volume":"15","author":"Bernal","year":"2008","journal-title":"Cell Death Differ."},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib10","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","article-title":"Landscape of genomic alterations in pituitary adenomas","volume":"23","author":"Bi","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7424","key":"10.1016\/j.mce.2025.112598_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41588-023-01460-5","article-title":"SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response","volume":"55","author":"Bland","year":"2023","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib14","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib15","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"Casar-Borota","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib16","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","article-title":"Identification of recurrent USP48 and BRAF mutations in Cushing's disease","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib17","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.18632\/aging.202304","article-title":"Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype","volume":"13","author":"Chen","year":"2020","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2010.02.012","article-title":"Pituitary senescence: the evolving role of Pttg","volume":"326","author":"Chesnokova","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"issue":"9","key":"10.1016\/j.mce.2025.112598_bib19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ph14090872","article-title":"Peptide receptor radionuclide therapy and primary brain tumors: an overview","volume":"14","author":"Cimini","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib20","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-Targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2025.112598_bib21","doi-asserted-by":"crossref","unstructured":"Cusan M, Shen H, Zhang B, Liao A, Yang L, Jin M, et al. SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation. J. Clin. Investig. 133(17):e163325.","DOI":"10.1172\/JCI163325"},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12022-019-09587-0","article-title":"The genomic landscape of sporadic prolactinomas","volume":"30","author":"De Sousa","year":"2019","journal-title":"Endocr. Pathol."},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib23","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.2008-0643","article-title":"Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas","volume":"93","author":"Dekkers","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas\u2014diagnosis and emerging treatments","volume":"10","author":"Di Ieva","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/cns-2016-0011","article-title":"Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy","volume":"5","author":"Donovan","year":"2016","journal-title":"CNS Oncol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J. Personalized Med."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib28","first-page":"125","article-title":"Fibroblast growth factor receptor-4 expression in pituitary adenomas is associated with aggressive tumor features","volume":"130","author":"Durcan","year":"2022","journal-title":"Exp. Clin. Endocrinol. Diabetes Off. J Ger. Soc. Endocrinol. Ger. Diabetes Assoc."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib29","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP mutation\u2012positive child","volume":"104","author":"Dutta","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2025.112598_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2826.2011.02129.x","article-title":"Histone acetylation patterns of typical and atypical pituitary adenomas indicate epigenetic shift of these tumours","volume":"23","author":"Ebrahimi","year":"2011","journal-title":"J. Neuroendocrinol."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2265.2006.02735.x","article-title":"A mutation and expression analysis of the oncogene BRAF in pituitary adenomas","volume":"66","author":"Ewing","year":"2007","journal-title":"Clin. Endocrinol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: a systematic review","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2265.2006.02630.x","article-title":"Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study","volume":"65","author":"Filippella","year":"2006","journal-title":"Clin. Endocrinol."},{"issue":"20","key":"10.1016\/j.mce.2025.112598_bib35","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib36","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib37","article-title":"Treatment of an aggressive gonadotroph pituitary neuroendocrine tumor with 177 Lutetium DOTATATE radionuclide therapy","volume":"2","author":"Gandhi","year":"2024","journal-title":"JCEM Case Rep."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.14645","article-title":"Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy","volume":"98","author":"Goichot","year":"2023","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13046-022-02245-0","article-title":"The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1","volume":"41","author":"Guo","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"6041","key":"10.1016\/j.mce.2025.112598_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib42","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan society for hypothalamic and pituitary tumors","volume":"98","author":"Hirohata","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib43","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","article-title":"Patients with rare cancers in the drug rediscovery protocol (DRUP) benefit from genomics-guided treatment","volume":"28","author":"Hoes","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib44","first-page":"1","article-title":"The two sides of chromosomal instability: drivers and brakes in cancer","volume":"9","author":"Hosea","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib45","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12020-019-02145-y","article-title":"Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours","volume":"67","author":"Iacovazzo","year":"2020","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib47","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","volume":"187","author":"Ilie","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2025.112598_bib46","unstructured":"WHO classification of tumours, 5th edition: Endocrine and neuroendocrine tumours. (International Agency for Research on Cancer. Lyon, France, 2022).[Internet]. [cited 2024 May 20]. Available from: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.mce.2025.112598_bib49","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s007010070003","article-title":"Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas","volume":"142","author":"Iuchi","year":"2000","journal-title":"Acta Neurochir."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib50","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0070","article-title":"Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors","volume":"32","author":"Jentus","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib51","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/eje.0.143r001","article-title":"Cyclin D and cyclin E expression in normal and adenomatous pituitary","volume":"143","author":"Jordan","year":"2000","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11102-011-0341-0","article-title":"New targeted therapies in pituitary carcinoma resistant to temozolomide","volume":"15","author":"Jouanneau","year":"2012","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib53","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/jc.2004-2231","article-title":"Clinical review: diagnosis and management of pituitary carcinomas","volume":"90","author":"Kaltsas","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"30","key":"10.1016\/j.mce.2025.112598_bib54","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1038\/sj.onc.1208659","article-title":"Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells","volume":"24","author":"Kim","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib55","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/carcin\/bgl202","article-title":"Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity","volume":"28","author":"Kim","year":"2007","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib56","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s11102-014-0630-5","article-title":"Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells","volume":"18","author":"Kitchen","year":"2015","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib57","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mce.2025.112598_bib58","article-title":"Temozolomide-induced shrinkage of invasive pituitary adenoma in patient with nelson's syndrome: a case report and review of the literature","volume":"2015","author":"Kurowska","year":"2015","journal-title":"Case Rep. Endocrinol."},{"key":"10.1016\/j.mce.2025.112598_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.576027","article-title":"Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy","author":"Lamb","year":"2020","journal-title":"Front Endocrinol 11:576027."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40478-020-01067-5","article-title":"Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis","volume":"8","author":"Lasolle","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib61","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11102-010-0249-0","article-title":"MGMT immunoexpression in aggressive pituitary adenoma and carcinoma","volume":"13","author":"Lau","year":"2010","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib62","first-page":"656","article-title":"Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness","volume":"81","author":"LeRiche","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2025.112598_bib63","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1673-8527(08)60122-8","article-title":"Histone acetyltransferase p300 regulates the expression of human pituitary tumor transforming gene (hPTTG)","volume":"36","author":"Li","year":"2009","journal-title":"J. Genet Genomics"},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib64","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib65","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1210\/jcem.84.10.6066","article-title":"Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors","volume":"84","author":"Lidhar","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1677\/ERC-08-0167","article-title":"Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors","volume":"16","author":"Lin","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib67","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00401-024-02736-8","article-title":"Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors","volume":"147","author":"Lin","year":"2024","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.mce.2025.112598_bib69","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3389\/fendo.2019.00785","article-title":"Expression of EGFR in pituitary corticotroph adenomas and its relationship with tumor behavior","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib70","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02738884","article-title":"Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas","volume":"10","author":"Lloyd","year":"1999","journal-title":"Endocr. Pathol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib72","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12022-015-9383-6","article-title":"Immune cell infiltrates in pituitary adenomas: more macrophages in larger adenomas and more T cells in growth hormone adenomas","volume":"26","author":"Lu","year":"2015","journal-title":"Endocr. Pathol."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib74","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.3390\/cancers15102710","article-title":"The effects of peptide receptor radionuclide therapy on the neoplastic and normal pituitary","volume":"15","author":"Marques","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s40478-019-0830-3","article-title":"Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours","volume":"7","author":"Marques","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"issue":"9","key":"10.1016\/j.mce.2025.112598_bib76","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/jc.2002-020309","article-title":"Vascular endothelial growth factor, its receptor KDR\/Flk-1, and pituitary tumor transforming gene in pituitary tumors","volume":"87","author":"McCabe","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib77","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-2362.2011.02520.x","article-title":"Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status","volume":"41","author":"McCormack","year":"2011","journal-title":"Eur. J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib78","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11102-012-0406-8","article-title":"MGMT expression and pituitary tumours: relationship to tumour biology","volume":"16","author":"McCormack","year":"2013","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib79","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"47","key":"10.1016\/j.mce.2025.112598_bib80","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01114-3","article-title":"Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression","volume":"24","author":"Mei","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.mce.2025.112598_bib82","author":"Melmed"},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11060-018-03016-8","article-title":"TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas","volume":"141","author":"Miyake","year":"2019","journal-title":"J. Neuro Oncol."},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib84","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/modpathol.3800118","article-title":"Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas","volume":"17","author":"Onguru","year":"2004","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib85","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","article-title":"Anti-VEGF therapy in pituitary carcinoma","volume":"15","author":"Ortiz","year":"2012","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib86","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/a-1260-3975","article-title":"Bevacizumab in aggressive pituitary adenomas \u2013 experience with 3 patients","volume":"129","author":"Osterhage","year":"2021","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"15_Suppl. l","key":"10.1016\/j.mce.2025.112598_bib87","article-title":"Metastatic ACTH-producing pituitary carcinoma managed with combination pasireotide and bevacizumab following failure of temozolamide therapy: a case report","volume":"31","author":"O'Riordan","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.mce.2025.112598_bib88","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib89","first-page":"842","article-title":"H-ras mutations in human pituitary carcinoma metastases","volume":"78","author":"Pei","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.mce.2025.112598_bib91","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa520","article-title":"Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion","volume":"105","author":"Principe","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib92","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1210\/jc.2003-031489","article-title":"Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness","volume":"89","author":"Qian","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib93","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/labinvest.3700248","article-title":"Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas","volume":"85","author":"Qian","year":"2005","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib94","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"22","key":"10.1016\/j.mce.2025.112598_bib96","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.mce.2025.112598_bib97","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-Term survival after transformation of an adrenocorticotropic hormone-secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma","volume":"122","author":"Rotman","year":"2019","journal-title":"World Neurosurg."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","volume":"156","author":"Saeger","year":"2007","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib99","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1066896909356105","article-title":"Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes","volume":"18","author":"Salehi","year":"2010","journal-title":"Int. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11060-011-0532-6","article-title":"MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas","volume":"104","author":"Salehi","year":"2011","journal-title":"J. Neuro Oncol."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib101","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11102-012-0434-4","article-title":"Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence","volume":"16","author":"S\u00e1nchez-Ortiga","year":"2013","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.mce.2025.112598_bib102","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3390\/jcm8050695","article-title":"Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors","volume":"8","author":"Sato","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.mce.2025.112598_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/srep16965","article-title":"EZH2 is highly expressed in pituitary adenomas and associated with proliferation","volume":"5","author":"Schult","year":"2015","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/path.833","article-title":"CDKN2A\/p16 inactivation is related to pituitary adenoma type and size","volume":"193","author":"Seemann","year":"2001","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib106","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","article-title":"Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report","volume":"91","author":"Shah","year":"2022","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","article-title":"Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours","volume":"189","author":"Simon","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2025.112598_bib137","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib109","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","article-title":"Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?","volume":"184","author":"Sol","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2025.112598_bib115","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/cr.2016.114","article-title":"The genome-wide mutational landscape of pituitary adenomas","volume":"26","author":"Song","year":"2016","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.mce.2025.112598_bib110","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/cancers15071967","article-title":"Precision oncology: evolving clinical trials across tumor types","volume":"15","author":"Song","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib111","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3892\/ijo.2017.4120","article-title":"Trophic and neurotrophic factors in human pituitary adenomas","volume":"51","author":"Spoletini","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.mce.2025.112598_bib112","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00262-020-02611-x","article-title":"Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor","volume":"69","author":"Suteau","year":"2020","journal-title":"Cancer Immunol Immunother CII"},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib113","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/02688697.2021.1967881","article-title":"Aggressive pituitary adenoma in the context of Lynch syndrome: a case report and literature review on this rare coincidence","volume":"38","author":"Teuber","year":"2024","journal-title":"Br. J. Neurosurg."},{"issue":"4","key":"10.1016\/j.mce.2025.112598_bib114","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","article-title":"p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions","volume":"38","author":"Thapar","year":"1996","journal-title":"Neurosurgery"},{"key":"10.1016\/j.mce.2025.112598_bib116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","article-title":"Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection","volume":"41","author":"Touma","year":"2017","journal-title":"J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib117","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"22","key":"10.1016\/j.mce.2025.112598_bib118","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD anderson cancer center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.mce.2025.112598_bib119","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1210\/jc.2017-02332","article-title":"Reduced expression of mismatch repair genes MSH6\/MSH2 directly promotes pituitary tumor growth via the ATR\u2013chk1 pathway","volume":"103","author":"Uraki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21082831","article-title":"MSH6\/2 and PD-L1 expressions are associated with tumor growth and invasiveness in silent pituitary adenoma subtypes","volume":"21","author":"Uraki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib121","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.3390\/ijms21082831","article-title":"MSH6\/2 and PD-L1 expressions are associated with tumor growth and invasiveness in silent pituitary adenoma subtypes","volume":"21","author":"Uraki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.mce.2025.112598_bib122","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukaemia","volume":"365","author":"Wang","year":"2011","journal-title":"NEJM"},{"issue":"49","key":"10.1016\/j.mce.2025.112598_bib123","article-title":"Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.mce.2025.112598_bib124","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","article-title":"Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review","volume":"124","author":"Wang","year":"2019","journal-title":"World Neurosurg."},{"key":"10.1016\/j.mce.2025.112598_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111083","article-title":"Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas","volume":"520","author":"Wei","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2025.112598_bib126","doi-asserted-by":"crossref","first-page":"726448","DOI":"10.3389\/fendo.2021.726448","article-title":"The upregulation of molecules related to tumor immune escape in human pituitary adenomas","volume":"12","author":"Xi","year":"2021","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5306\/wjco.v11.i2.91","article-title":"Pituitary carcinoma: two case reports and review of literature","volume":"11","author":"Xu","year":"2020","journal-title":"World J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib128","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nrendo.2012.54","article-title":"The pituitary tumour epigenome: aberrations and prospects for targeted therapy","volume":"8","author":"Yacqub-Usman","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib129","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1210\/en.2012-1231","article-title":"Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced Re-expression","volume":"153","author":"Yacqub-Usman","year":"2012","journal-title":"Endocrinology"},{"issue":"22","key":"10.1016\/j.mce.2025.112598_bib130","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.18632\/oncotarget.26775","article-title":"Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes","volume":"10","author":"Yagnik","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-006-9316-9","article-title":"Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas","volume":"83","author":"Yoshino","year":"2007","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.mce.2025.112598_bib132","author":"Zhang"},{"issue":"2","key":"10.1016\/j.mce.2025.112598_bib133","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1210\/jcem.84.2.5432","article-title":"Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas","volume":"84","author":"Zhang","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2025.112598_bib134","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.mce.2025.112598_bib135","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.7150\/thno.53749","article-title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.mce.2025.112598_bib136","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720725001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720725001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T06:17:11Z","timestamp":1753683431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720725001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":134,"alternative-id":["S0303720725001492"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2025.112598","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2025.112598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112598"}}